Neufeld A H, Ledgard S E, Yoza B K
Invest Ophthalmol Vis Sci. 1983 May;24(5):527-34.
Adrenergic agonists stimulate the synthesis of cyclic AMP by incubated rabbit corneas with the following order of potency: isoproterenol greater than epinephrine greater than norepinephrine. These agonists have the same order of potency when displacing the specific, beta-adrenergic radioligand, 3H-dihydroalprenolol, from beta-adrenergic receptors on membranes prepared from corneal epithelium. At another locus, serotonin stimulates cyclic AMP synthesis. Inhibition of stimulation in vitro by lysergic acid diethylamide, methysergide, cyproheptadine, and spiroperidol demonstrates the specificity of this pathway for serotonin. Topical epinephrine causes subsensitivity or decreased responsiveness of the beta-adrenergic pathway. There is loss of approximately half the beta-adrenergic receptors from the cornea and a similar loss of epinephrine-stimulated cyclic AMP synthesis, both of which return to control levels in 96 hrs. There is no change in affinity for catecholamines and no loss of responsiveness to prostaglandin E2 or serotonin. Pretreatment with nialamide or subsequent treatment with additional epinephrine does not cause further loss of responsiveness. Supersensitivity or increased responsiveness of this pathway occurs following superior cervical ganglionectomy. Topical serotonin causes decreased responsiveness of the serotonergic pathway. When potentiated by nialamide, serotonin causes almost complete loss of serotonin-stimulated cyclic AMP synthesis for 24-48 hrs. There is no loss of responsiveness to epinephrine. Increased responsiveness of this pathway does not occur following superior cervical ganglionectomy. The authors conclude that the corneal epithelium has both beta 2-adrenergic and serotonin-2 pathways, and each pathway exhibits altered responsiveness by similar mechanisms. In response to exogenous or endogenous stimulation, the beta-adrenergic responsive cells and the serotonergic responsive cells apparently regulate the total number of pathway-specific receptors on their surfaces. Furthermore, the authors postulate that two populations of beta-adrenergic responsive cells exist; those on the apical surface of the epithelium that respond to catecholamine in the tears and those near the basal surface that respond to neuronal catecholamine.
肾上腺素能激动剂刺激离体兔角膜合成环磷酸腺苷(cAMP),其效力顺序如下:异丙肾上腺素>肾上腺素>去甲肾上腺素。当这些激动剂从角膜上皮制备的膜上的β-肾上腺素能受体上取代特异性β-肾上腺素能放射性配体3H-二氢阿普洛尔时,它们也具有相同的效力顺序。在另一个位点,5-羟色胺刺激cAMP合成。麦角酸二乙胺、甲基麦角新碱、赛庚啶和螺哌啶在体外对这种刺激的抑制作用证明了该途径对5-羟色胺的特异性。局部应用肾上腺素会导致β-肾上腺素能途径的超敏反应或反应性降低。角膜中约有一半的β-肾上腺素能受体丧失,肾上腺素刺激的cAMP合成也有类似程度的丧失,两者在96小时后均恢复到对照水平。对儿茶酚胺的亲和力没有变化,对前列腺素E2或5-羟色胺的反应性也没有丧失。用尼亚酰胺预处理或随后再用肾上腺素处理不会导致反应性进一步丧失。颈上神经节切除术后,该途径会出现超敏反应或反应性增加。局部应用5-羟色胺会导致5-羟色胺能途径的反应性降低。当用尼亚酰胺增强时,5-羟色胺会导致5-羟色胺刺激的cAMP合成在24 - 48小时内几乎完全丧失。对肾上腺素的反应性没有丧失。颈上神经节切除术后,该途径不会出现反应性增加。作者得出结论,角膜上皮具有β2-肾上腺素能和5-羟色胺-2途径,并且每个途径通过相似的机制表现出反应性改变。对外源性或内源性刺激的反应中,β-肾上腺素能反应性细胞和5-羟色胺能反应性细胞显然会调节其表面途径特异性受体的总数。此外,作者推测存在两类β-肾上腺素能反应性细胞;一类位于上皮细胞顶端表面,对泪液中的儿茶酚胺起反应,另一类位于基底表面附近,对神经元儿茶酚胺起反应。